KCNH2 and cancer: For example, roscovitine, a cyclin dependent kinase inhibitor currently in phase II trials for treating cancers, is able to inhibit kv11.1 in clinically relevant doses [145,146,147] and yet, no adverse effects of arrhythmia have been reported thus far.